MWNA
RNAM

Marshall Wace North America’s Avidity Biosciences RNAM Stock Holding History

Marshall Wace North America’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$6.15M Sell
249,755
-86,700
-26% -$1.88M 0.03% 457
2021
Q2 		$8.31M Buy
+336,455
New +$7.83M 0.03% 411
2020
Q3 		– Sell
-35,182
Closed -$994K – 1437
2020
Q2 		$994K Buy
+35,182
New +$1.01M 0.01% 760

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Marshall Wace North America's RNAM Position: Q3 2021 in Review

Marshall Wace North America reduced its Avidity Biosciences (RNAM) stake by 26% in Q3 2021, selling an estimated $1.88M and leaving 249,755 shares worth $6.15M. The position accounts for 0.03% of the portfolio, ranked #457.

Marshall Wace North America first reported a position in RNAM in Q2 2020 and has held it in 3 quarters since. The position peaked at $8.31M in Q2 2021. 111 funds tracked by Wall St. Rank hold RNAM as of Q3 2021.

  • Marshall Wace North America held 249,755 shares of Avidity Biosciences worth $6.15M as of Q3 2021.
  • Marshall Wace North America sold 86,700 Avidity Biosciences shares in Q3 2021, an estimated $1.88M.
  • Avidity Biosciences made up 0.03% of Marshall Wace North America's portfolio in Q3 2021, its #457 holding.
  • Marshall Wace North America first reported a position in Avidity Biosciences in Q2 2020 and has held it in 3 quarters since.
  • Marshall Wace North America's Avidity Biosciences position peaked at $8.31M in Q2 2021.
  • 111 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.